Earnings summaries and quarterly performance for Indivior Pharmaceuticals.
Research analysts who have asked questions during Indivior Pharmaceuticals earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for INDV
Also covers: AVDL, BFLY, BVS +17 more
David Amsellem
Piper Sandler Companies
4 questions for INDV
Also covers: ABBV, ALKS, AMGN +27 more
CG
Christian Glennie
Stifel
3 questions for INDV
PC
Paul Cuddon
Deutsche Numis
3 questions for INDV
Also covers: MXCT
Thibault Boutherin
Morgan Stanley
2 questions for INDV
Also covers: ALVO, EVO, GRFS +2 more
BF
Brandon Folkes
Rodman & Renshaw
1 question for INDV
Also covers: ACHV, ANIP, AVDL +10 more
BB
Brian Balchin
Jefferies
1 question for INDV
CB
Carl Byrnes
Northland Capital Markets
1 question for INDV
Also covers: ALVO, BLFS, BWAY +6 more
DD
Dennis Ding
Jefferies Financial Group Inc.
1 question for INDV
Also covers: ARDX, CARA, FOLD +6 more
Recent press releases and 8-K filings for INDV.
Indivior Completes Redomiciliation to the United States
INDV
Corporate Governance
Delisting/Listing Issues
- Indivior completed its redomiciliation from the United Kingdom to the United States, with Indivior Pharmaceuticals, Inc., a Delaware corporation, becoming the new parent company.
- Indivior PLC was renamed Indivior Ltd. and is now a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc..
- The common stock of Indivior Pharmaceuticals, Inc. began trading on Nasdaq under the symbol "INDV" on January 26, 2026, replacing Indivior PLC ordinary shares which ceased trading on January 23, 2026.
- Shareholders of Indivior PLC received one new Indivior Pharmaceuticals, Inc. common share for each Indivior PLC ordinary share held.
Jan 26, 2026, 12:01 PM
Indivior Completes Redomiciliation to the United States
INDV
Delisting/Listing Issues
Proxy Vote Outcomes
- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) completed its redomiciliation from the United Kingdom to the United States on January 26, 2026.
- A new Delaware corporation, Indivior Pharmaceuticals, Inc. ("IPI"), has become the new parent company, with Indivior PLC renamed Indivior Ltd. and becoming a wholly-owned subsidiary of IPI.
- The common stock of IPI will continue to trade on Nasdaq under the symbol "INDV".
- Shareholders of Indivior PLC received one new IPI common share for each Indivior PLC ordinary share held.
- Indivior expects benefits from the redomiciliation to include strengthening its U.S. capital markets presence, increasing potential U.S. equity indexation, and simplifying corporate governance.
Jan 26, 2026, 12:00 PM
Indivior PLC Provides Full-Year 2026 Financial Guidance and Business Update
INDV
Guidance Update
Revenue Acceleration/Inflection
- Indivior PLC issued full-year 2026 financial guidance, projecting Total Net Revenue between $1,125 million and $1,195 million and Adjusted EBITDA between $535 million and $575 million.
- The company expects Total SUBLOCADE Net Revenue to reach $905 million to $945 million, reflecting 11% growth at the midpoint, driven by an acceleration of U.S. SUBLOCADE dispense unit growth to the mid-teens.
- Non-GAAP Operating Expenses are forecast to be $430 million to $450 million, benefiting from at least $150 million in annual savings due to a simplified operating model.
- Indivior anticipates 35% Adjusted EBITDA growth and a 14 percentage point expansion in Adjusted EBITDA margin to 48% in 2026, as it enters Phase II of its Action Agenda focused on acceleration.
Jan 8, 2026, 12:05 PM
Indivior Announces Positive Clinical Trial Results for SUBLOCADE
INDV
Product Launch
- Indivior PLC announced that a clinical trial published in JAMA Network Open showed its SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence in individuals with moderate-to-severe opioid use disorder (OUD).
- Both the 100-mg and 300-mg monthly maintenance doses were well-tolerated with no new safety signals identified.
- Post-hoc analyses indicated that the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.
Dec 17, 2025, 4:30 PM
Indivior PLC Shareholders Approve Scheme of Arrangement and Corporate Restructuring
INDV
M&A
Proxy Vote Outcomes
Delisting/Listing Issues
- On December 11, 2025, Indivior PLC shareholders approved amended and restated articles of association to facilitate a Scheme of Arrangement.
- This Scheme of Arrangement will result in Indivior PLC becoming a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc., with all Indivior PLC shareholders becoming shareholders of Indivior Pharmaceuticals, Inc..
- Shareholders overwhelmingly approved the Scheme of Arrangement at a Court Meeting, with 94,968,161 votes for and 46,544 votes against.
- At an Extraordinary General Meeting on the same date, shareholders also passed all related special resolutions, including authorizing the reduction of share capital, issuance of new shares, and the re-registration of the company as a private company limited by shares.
- The completion of the Scheme of Arrangement remains subject to the sanction of the High Court of Justice, with a hearing anticipated on January 22, 2026.
Dec 15, 2025, 9:04 PM
Indivior Outlines Strategic Vision and Cost Optimization Initiatives
INDV
Management Change
Guidance Update
New Projects/Investments
- Indivior has implemented an "Indivior Action Agenda" to maximize business value, including a $150 million reduction in OPEX and a commitment that 2026 OPEX will not exceed $450 million. This is expected to lead to significant margin improvement in 2026.
- The company is optimizing its international business by reducing its presence from 41 countries to 4 countries (Canada, Australia, France, Germany), which represent 77% of forecasted net revenue and 94% of forecasted EBITDA for the Rest of World business.
- Commercial support for OPVEE has been ceased due to unfavorable market dynamics, allowing for greater focus on maximizing the core asset, SUBLOCADE.
- A significant untapped opportunity exists for SUBLOCADE in commercially covered patients, who represent 60% of covered lives but only 25% of prescriptions. Indivior plans aggressive investment in consumer (DTC) efforts to drive long-acting injectable market penetration, currently at 8%.
- Indivior's R&D pipeline includes Indivior 6001 and Indivior 2000 with phase two data readouts expected in early Q2 2026. Future M&A will target commercial stage assets with $200 million+ peak sales potential in adjacent therapeutic areas.
Dec 2, 2025, 8:30 PM
Indivior Outlines Strategic Vision, Cost Optimization, and SUBLOCADE Growth Initiatives
INDV
Guidance Update
New Projects/Investments
M&A
- Indivior has implemented an "Action Agenda" to maximize business value, which includes removing $150 million of OPEX and targeting 2026 OPEX not exceeding $450 million.
- The company is optimizing its Rest of World business, reducing its presence from 41 countries to 4 (Canada, Australia, France, and Germany), which collectively represent 77% of forecasted net revenue and 94% of forecasted EBITDA.
- Commercial support for OPVEE has been discontinued due to market dynamics and lack of synergy with the SUBLOCADE business.
- Indivior is prioritizing investment in SUBLOCADE, which has 88% payer access and a market share stabilized in the mid-70%, with plans for aggressive consumer campaigns to drive long-acting injectable penetration.
- Future growth will also involve commercial stage acquisitions with over $200 million peak sales potential in adjacent therapeutic areas.
Dec 2, 2025, 8:30 PM
Indivior Concludes Legacy U.S. Department of Justice Matter
INDV
Legal Proceedings
- Indivior PLC announced on November 20, 2025, the conclusion of its legacy U.S. Department of Justice (DOJ) matter.
- The company resolved the matter by paying the outstanding obligation of $295 million.
- This payment was funded with Indivior's cash on hand, leading to the termination of the resolution agreement with the DOJ.
- CEO Joe Ciaffoni stated that this action removes a significant liability and simplifies the company's capital structure.
Nov 20, 2025, 9:01 PM
Indivior PLC to Redomicile to U.S. with New Nasdaq-Listed Holding Company
INDV
Delisting/Listing Issues
M&A
Proxy Vote Outcomes
- Indivior PLC is undergoing a redomiciliation from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc., a new Delaware corporation, as its ultimate holding company.
- Under the scheme, Indivior Shareholders will receive one Indivior Pharmaceuticals Share for every one Indivior Share held.
- The new Indivior Pharmaceuticals Shares will be listed on Nasdaq, with trading anticipated to commence at the end of January 2026, following the expected effective date of the Scheme.
- The strategic move aims to maximize the benefits of the Group's U.S. stock listing, including expanding U.S. capital markets presence, increasing U.S. equity indexation, and simplifying corporate governance.
- Post-redomiciliation, Indivior Pharmaceuticals will comply with U.S. corporate governance standards, and the U.K. City Code on Takeovers and Mergers will no longer apply.
Nov 14, 2025, 2:05 PM
Indivior discusses Q3 results, Sublocade growth, and cost savings
INDV
Guidance Update
Layoffs
New Projects/Investments
- Indivior reported a strong Q3 beat and raise, with Sublocade showing 10% growth this year, and announced $150 million in cost savings for next year, reducing OPEX to no more than $450 million.
- The company expects Sublocade sales to surpass $1 billion, with current year guidance of $825 million-$845 million, and aims to increase long-acting injectable (LAI) penetration from 8% to 20-30%.
- The $150 million cost savings include a 30% reduction in headcount and the discontinuation of non-essential spend and certain product/market activities.
- Indivior plans to acquire new commercial stage assets with potential revenue of at least $200 million and has a history of $400 million in share buybacks.
Nov 13, 2025, 1:40 PM
Quarterly earnings call transcripts for Indivior Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more